[시장보고서]세계의 급성 반복 발작 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2033년)

세계의 급성 반복 발작 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2033년)

Global Acute Repetitive Seizures Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033

상품코드 : 1820598

리서치사 : Value Market Research

발행일 : 2025년 08월

페이지 정보 : 영문 131 Pages

라이선스 & 가격 (부가세 별도)

US $ 3,920

￦ 5,838,000

PDF & Excel (Single User License)

PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 전자파일의 이용 범위와 동일합니다.

US $ 4,730

￦ 7,044,000

PDF & Excel (10-user License)

PDF 및 Excel 보고서를 동일 기업 내 10명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 전자파일의 이용 범위와 동일합니다.

US $ 7,430

￦ 11,065,000

PDF & Excel (Corporate User License)

PDF 및 Excel 보고서를 동일 기업 내 모든 사용자가 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 전자파일의 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

세계의 급성 반복 발작 시장은 2024년 37억 달러에서 2033년에는 108억 6,000만 달러에 이를 전망이며, 큰 성장이 예상됩니다. 2025-2033년 연평균 복합 성장률(CAGR) 12.72%로 성장할 것으로 예측됩니다.

급성 반복 발작 시장은 발작군을 관리하고 입원을 줄이기 위한 신속하고 효과적인 개입의 필요성에 의해 성장할 전망입니다. 비강 벤조디아제핀 제형과 설하 제형을 포함한 새로운 구조 요법은 투여의 용이성과 환자의 컴플라이언스를 향상시킵니다. 향후 개발에서는 맞춤 치료 프로토콜과 디지털 발작 모니터링 장치의 통합이 주목됩니다.

또한 발작성 질환에 대한 인식과 진단이 증가함에 따라 환자 집단이 확대되고 있습니다. 신경 약리학과 약물 전달 시스템의 발전으로 치료 효과와 안전성 프로파일이 향상되었습니다. 원격 의료 및 원격 환자 모니터링의 통합은 적시에 개입과 케어 코디네이션을 촉진합니다. 간질 치료의 진화에 따라 급성 반복 발작 시장은 앞으로도 혁신을 계속하고 환자의 결과와 QOL을 개선하는 선진적인 치료법을 제공해 나갈 것입니다.

지역별 전망
서문
북미의 매출 분석
- 개요, 분석 및 예측
- 북미 : 부문별
- 북미 국가별
- 미국
- 캐나다
- 멕시코
유럽의 매출 분석
- 개요, 분석 및 예측
- 유럽 : 부문별
- 유럽 국가별
- 영국
- 프랑스
- 독일
- 이탈리아
- 러시아
- 기타 유럽
아시아태평양의 매출 분석
- 개요, 분석 및 예측
- 아시아태평양 : 부문별
- 아시아태평양 국가별
- 중국
- 인도
- 일본
- 한국
- 호주
- 동남아시아
- 기타 아시아태평양
라틴아메리카의 매출 분석
- 개요, 분석 및 예측
- 라틴아메리카 : 부문별
- 라틴아메리카 국가별
- 브라질
- 아르헨티나
- 페루
- 칠레
- 기타 라틴아메리카
중동 및 아프리카의 매출 분석
- 개요, 분석 및 예측
- 중동 및 아프리카 : 부문별
- 중동 및 아프리카 국가별 일람
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 남아프리카
- 기타 중동 및 아프리카

제9장 급성 반복 발작 기업 경쟁 구도

급성 반복 발작 시장의 경쟁
제휴, 협력 및 합의
합병 및 인수
신제품 출시
기타 개발

제10장 기업 프로파일

주요 기업의 시장 점유율 분석
시장 집중도
AdvaCare Pharma Limited
Esteive Therapeutics
Bausch Health Companies
Lupin Limited
Neuracle Lifesciences
Neurelis
Pfizer
Sanofi
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries
UCB SA
Veriton Pharma

AJY

영문 목차

영문목차

Global Acute Repetitive Seizures Market is poised to witness substantial growth, reaching a value of USD 10.86 Billion by the year 2033, up from USD 3.7 Billion attained in 2024. The market is anticipated to display a Compound Annual Growth Rate (CAGR) of 12.72% between 2025 and 2033.

The acute repetitive seizures market is poised for growth driven by the need for rapid, effective interventions to manage seizure clusters and reduce hospitalization. Novel rescue therapies, including intranasal benzodiazepines and sublingual formulations, are improving ease of administration and patient compliance. Future developments will focus on personalized treatment protocols and integration with digital seizure monitoring devices.

Additionally, increasing awareness and diagnosis of seizure disorders are expanding patient populations. Advances in neuropharmacology and drug delivery systems are enhancing therapeutic efficacy and safety profiles. The integration of telemedicine and remote patient monitoring is facilitating timely intervention and care coordination. As epilepsy management evolves, the acute repetitive seizures market will continue to innovate, delivering advanced therapies that improve patient outcomes and quality of life.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

LIST OF SEGMENTS COVERED

This section of the Acute Repetitive Seizures market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

USL-261
Diastat Rectal Gel (DRG)
NRL-1
Other Products

By Route of Administration

Intranasal
Rectal
Oral
Other Routes of Administration

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
List of Companies Profiled in the report
AdvaCare Pharma Limited, Aquestive Therapeutics, Bausch Health Companies, Lupin Limited, Neuracle Lifesciences, Neurelis, Pfizer, Sanofi, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries, UCB S.A., Veriton Pharma

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. ACUTE REPETITIVE SEIZURES - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Product
- 3.7.2 Market Attractiveness Analysis By Route of Administration
- 3.7.3 Market Attractiveness Analysis By Distribution Channel
- 3.7.4 Market Attractiveness Analysis By Regions

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL ACUTE REPETITIVE SEIZURES MARKET ANALYSIS BY PRODUCT

5.1. Overview By Product
5.2. Historical and Forecast Data Analysis By Product
5.3. USL-261 Historic and Forecast Sales By Regions
5.4. Diastat Rectal Gel (DRG) Historic and Forecast Sales By Regions
5.5. NRL-1 Historic and Forecast Sales By Regions
5.6. Other Products Historic and Forecast Sales By Regions

6. GLOBAL ACUTE REPETITIVE SEIZURES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

6.1. Overview By Route of Administration
6.2. Historical and Forecast Data Analysis By Route of Administration
6.3. Intranasal Historic and Forecast Sales By Regions
6.4. Rectal Historic and Forecast Sales By Regions
6.5. Oral Historic and Forecast Sales By Regions
6.6. Other Routes of Administration Historic and Forecast Sales By Regions

7. GLOBAL ACUTE REPETITIVE SEIZURES MARKET ANALYSIS BY DISTRIBUTION CHANNEL

7.1. Overview By Distribution Channel
7.2. Historical and Forecast Data Analysis By Distribution Channel
7.3. Hospital Pharmacies Historic and Forecast Sales By Regions
7.4. Retail Pharmacies Historic and Forecast Sales By Regions
7.5. Online Pharmacies Historic and Forecast Sales By Regions

8. GLOBAL ACUTE REPETITIVE SEIZURES MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE ACUTE REPETITIVE SEIZURES COMPANIES

9.1. Acute Repetitive Seizures Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF ACUTE REPETITIVE SEIZURES INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. AdvaCare Pharma Limited
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. Aquestive Therapeutics
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. Bausch Health Companies
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. Lupin Limited
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. Neuracle Lifesciences
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. Neurelis
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. Pfizer
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. Sanofi
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. Takeda Pharmaceutical Company Limited
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. Teva Pharmaceutical Industries
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments
10.13. UCB S.A.
- 10.13.1 Company Overview
- 10.13.2 Company Revenue
- 10.13.3 Products
- 10.13.4 Recent Developments
10.14. Veriton Pharma
- 10.14.1 Company Overview
- 10.14.2 Company Revenue
- 10.14.3 Products
- 10.14.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of privcompanies

한글목차

목차

제1장 서문

제2장 주요 요약

제3장 급성 반복 발작 : 산업 분석

제4장 밸류체인 분석

제5장 세계의 급성 반복 발작 시장 분석 : 제품별

제6장 세계의 급성 반복 발작 시장 분석 : 투여 경로별

제7장 세계의 급성 반복 발작 시장 분석 : 유통 채널별

제8장 세계의 급성 반복 발작 시장 분석 : 지역별